Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP: RHHBY )

39.14 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EDT, Apr 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,614
Open 39.14
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 39.14
Today's Range 39.14 - 39.14
52wk Range 29.20 - 44.31
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Roche Plans $50 Billion US Investment Over 5 Years With 12,000 New Jobs
Roche to invest $50 billion in U.S. over five years, adding 12,000+ jobs and expanding manufacturing, R&D, and export capacity across eight states. 
Via Benzinga
Roche's $50 Billion US Investment Commitment Includes New Facilities, 12,000 Jobs, Expanded R&D Hubs As Drug Tariffs Loom
Roche plans $50B investment in U.S. for manufacturing & research, as potential drug tariffs loom. Move to create 12,000 jobs & increase exports 
Via Benzinga
Topics World Trade
Exposures Tariff

Performance

YTD
+12.02%
+12.02%
1 Month
-8.79%
-8.79%
3 Month
+3.41%
+3.41%
6 Month
-2.64%
-2.64%
1 Year
+25.29%
+25.29%

More News

Read More
What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?
Via Benzinga
Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight
Via Benzinga
Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success
Via Benzinga
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline
Via Benzinga
Topics Government Supply Chain World Trade
Exposures Political Supply Chain Tariff
Why Roche Holding, Eli Lilly, and AstraZeneca Stocks Dropped Today
Via The Motley Fool
Topics Government World Trade
Exposures Political Tariff
Roche To Start Phase 3 Study For Alzheimer's Prospect This Year After New Data From Phase 2
Via Benzinga
Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death
Via Benzinga
Genentech and Roche Present Novel Therapeutic and Diagnostic Advancements in Alzheimer’s at AD/PD 2025
From Genentech
Via Business Wire
Why Is Pharma Giant Roche Stock Trading Lower On Wednesday?
Via Benzinga
IBD 50 Stock TG Therapeutics Rallies On A Setback For Chief Rival Roche
Via Investor's Business Daily
Genentech Provides Update on Phase III Ocrevus High Dose Study in People With Relapsing Multiple Sclerosis
From Genentech
Via Business Wire
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
Via Benzinga
Novartis New Data From Single-Dose Gene Therapy Shows Meaningful Efficacy, Safety In Patients With Spinal Muscular Atrophy
Via Benzinga
The Best Vanguard ETF to Invest $1,000 in Right Now
Via The Motley Fool
Topics ETFs
Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped
Via The Motley Fool
Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion
Via Investor's Business Daily
Roche Further Boosts Obesity Pipeline With Zealand Pharma Deal Worth $5.3 Billion For Weight Loss Drugs
Via Benzinga
FDA Accepts Supplemental Biologics License Application for Genentech’s Gazyva for the Treatment of Lupus Nephritis
From Genentech
Via Business Wire
FDA Approves Genentech’s TNKase® in Acute Ischemic Stroke in Adults
From Genentech
Via Business Wire
Roche Touts Food Allergy Drug As Superior Than Oral Immunotherapy
Via Benzinga
Phase III Study Shows Xolair May Be More Effective With Fewer Side Effects Than Oral Immunotherapy for the Treatment of Food Allergies
From Genentech
Via Business Wire
NovoCure Q4 EPS Misses, Revenue Matches
Via The Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.